Stockscreener 앱 받기
16.20
0.75%
0.12
시장 영업 전:
17.08
0.88
+5.43%
전일 마감가:
$16.08
열려 있는:
$16.49
하루 거래량:
502.39K
Relative Volume:
4.39
시가총액:
$510.69M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.37%
1개월 성능:
-26.03%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$15.90
$16.99
1주일 범위
$14.77
$17.79
52주 변동 폭
$13.88
$24.03
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1841 PAGE MILL RD, PALO ALTO
EVMN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
16.20 | 506.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
모두보기
Evommune Inc 주식(EVMN)의 최신 뉴스
Raymond James initiates Evommune stock with Strong Buy rating, $40 target - Investing.com
Evommune participates in a conference call with William Blair - MSN
Evommune’s EVO756 Trial Targets High-Need Urticaria Market: What Investors Should Watch - TipRanks
Evommune stock initiated with Buy rating at H.C. Wainwright on urticaria potential - Investing.com Nigeria
This Spire Global Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Benzinga
Evommune (EVMN) Receives 'Buy' Rating from HC Wainwright & Co. | - GuruFocus
Evommune initiated with a Buy at H.C. Wainwright - TipRanks
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stock - The Business Journals
Evommune (NYSE:EVMN) Trading 5.3% HigherTime to Buy? - MarketBeat
Evommune and BillionToOne climb on trading debut - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Evommune Director Makes Bold Move With Fresh Insider Buy - TipRanks
Hopfner buys Evommune (EVMN) shares worth $17,350 By Investing.com - Investing.com Nigeria
Hopfner buys Evommune (EVMN) shares worth $17,350 - Investing.com India
Evommune (NYSE:EVMN) Shares Down 4.7%Here's What Happened - MarketBeat
Evommune, Inc.(NYSE: EVMN) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - Reuters
Evommune (EVMN) awards 100,000 stock options to its Chief Medical Officer - Stock Titan
Evommune Prepares For Key Mid-2026 Trial Readouts, Advances Inflammation Pipeline - RTTNews
Silicon Valley biotech firm expands to 43,000 square feet after going public - The Business Journals
Buy Rating for Evommune, Inc. Driven by EVO756’s Promising Phase II Trial Potential - TipRanks
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Evommune, Inc. (EVMN) and Eli Lilly & Co (LLY) - The Globe and Mail
These Bay Area companies are IPO contenders in 2026 - The Business Journals
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace
Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating - TipRanks
CEO Pena Surrenders 28,138 Of Evommune Inc [EVMN] - TradingView — Track All Markets
Evommune, Inc. SEC 10-Q Report - TradingView — Track All Markets
EVMN: Net loss narrowed to $40.6M as license revenue grew and IPO proceeds extended cash runway into 2028 - TradingView — Track All Markets
Evommune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - marketscreener.com
EVMN: IPO proceeds and licensing revenue strengthen position ahead of key 2026 clinical readouts - TradingView — Track All Markets
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Evommune (EVMN) Stock Trends and Sentiment 2025 - MarketBeat
Biopharma funding normalizes as 2025 outperforms post-pandemic lows - BioWorld MedTech
Evommune, Inc. (EVMN) analyst ratings, estimates and forecasts - Yahoo Finance UK
Evommune (NYSE:EVMN) Upgraded at Zacks Research - Defense World
Evommune (EVMN) Competitors and Alternatives 2025 - MarketBeat
Evommune (NYSE:EVMN) Research Coverage Started at Evercore ISI - Defense World
Evommune (NYSE:EVMN) Shares See Activity on Sector Research Shift - Kalkine Media
Evommune (NYSE:EVMN) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Evommune initiated with an Outperform at William Blair - MSN
Evommune initiated with an Overweight at Cantor Fitzgerald - MSN
Evommune, Inc. (EVMN) options chain - Yahoo Finance UK
Evommune, Inc.: Revenue and Earnings Analysts Forecasts Revisions | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Target Price Consensus and Analysts Recommendations | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Dividend historical data and projections - marketscreener.com
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Leerink Partners - MarketBeat
Evommune initiated with an Overweight at Morgan Stanley - MSN
Evercore ISI initiates Evommune stock with Outperform rating on dermatology potential - Investing.com Australia
Evommune, Inc. (EVMN) Options Chain - Yahoo! Finance Canada
Leerink Partners initiates coverage on Evommune stock with Outperform rating By Investing.com - Investing.com South Africa
Evommune Inc (EVMN) 재무 분석
Evommune Inc (EVMN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):